Free tool
FAERS Monitor: Cetirizine Hydrochloride Allergy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022429 or its brand name (Cetirizine Hydrochloride Allergy, Cetirizine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
79,983
Serious
60,044
75% of reports
Hospitalization
25,302
Death reported
9,000
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective13,781
- fatigue13,767
- pain12,748
- rash10,518
- off label use10,250
- abdominal discomfort9,800
- alopecia9,656
- rheumatoid arthritis9,145
- systemic lupus erythematosus8,883
- pemphigus8,676
- swelling8,337
- hypersensitivity8,238
- glossodynia8,162
- headache8,142
- pruritus8,137
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 244 |
| 2005 | 246 |
| 2006 | 202 |
| 2007 | 278 |
| 2008 | 491 |
| 2009 | 436 |
| 2010 | 488 |
| 2011 | 772 |
| 2012 | 958 |
| 2013 | 989 |
| 2014 | 1,485 |
| 2015 | 2,185 |
| 2016 | 3,341 |
| 2017 | 3,253 |
| 2018 | 4,187 |
| 2019 | 5,111 |
| 2020 | 6,163 |
| 2021 | 8,587 |
| 2022 | 8,097 |
| 2023 | 7,366 |
| 2024 | 9,149 |
| 2025 | 9,499 |
| 2026 | 6,456 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,974,176 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigusSignal | 8,676 | 592.8 | 571.1 | 1,572,793 |
| glossodyniaSignal | 8,162 | 150.2 | 146.3 | 769,991 |
| systemic lupus erythematosusSignal | 8,883 | 87.4 | 85.4 | 570,052 |
| swellingSignal | 8,337 | 25.6 | 25.1 | 180,443 |
| rheumatoid arthritisSignal | 9,145 | 22.9 | 22.5 | 177,462 |
| abdominal discomfortSignal | 9,800 | 16.3 | 15.9 | 133,141 |
| alopeciaSignal | 9,656 | 13.5 | 13.3 | 107,684 |
| hypersensitivitySignal | 8,238 | 12.2 | 11.9 | 81,385 |
| rashSignal | 10,518 | 6.5 | 6.4 | 48,542 |
| pruritusSignal | 8,137 | 5.7 | 5.5 | 31,175 |
| painSignal | 12,748 | 5.6 | 5.5 | 47,984 |
| fatigueSignal | 13,767 | 4.7 | 4.6 | 41,112 |
| headacheSignal | 8,142 | 3.4 | 3.4 | 14,385 |
| off label useSignal | 10,250 | 3.1 | 3.0 | 15,062 |
| drug ineffectiveSignal | 13,781 | 2.8 | 2.7 | 16,430 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.